Previous 10 | Next 10 |
Veru Inc. (VERU) is expected to report $-0.2 for Q4 2023
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU). Following the onset of the COVID-19 pandemic, the Company pursued...
2023-10-04 10:05:55 ET More on Veru Veru Inc. (VERU) Q2 2023 Earnings Call Transcript Stay Away From Veru Until 2024 Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial information for Veru For further detai...
-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- Weight-loss drugs like Ozempic, Weg...
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the “tripledemic viruses”: Influenza, RSV, and SARS-CoV-2-- -- Based on high morta...
MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D.,...
-- Overall response rates of 12.5% are observed in the enobosarm group in a heavily pretreated population versus no responses in the standard of care active control arm. On average, enobosarm or active control was given in the 4 th line treatment in the metastatic setting whic...
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced that Mitchell Steiner, M.D., Chai...
2023-08-18 10:19:27 ET Gainers: Aditxt ( ADTX ) +50% . AlloVir ( ALVR ) +18% . Agenus ( AGEN ) +7% . Veru ( VERU ) +7% . Akari Therapeutics ( AKTX ) +6% . Losers: Evelo Biosciences ( EVLO ) -37% . Diffusi...
2023-08-10 14:30:21 ET Veru Inc. (VERU) Q2 2023 Earnings Conference Call August 09, 2023 04:30 PM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & Pres...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...